FXTM information and reviews
FXTM
93%
IronFX information and reviews
IronFX
92%
Libertex information and reviews
Libertex
91%
FXCC information and reviews
FXCC
90%
Markets.com information and reviews
Markets.com
89%
FxPro information and reviews
FxPro
88%
EUR/USD
1.1720
BTC/USD
42 648.00
GBP/USD
1.3685
USD/JPY
110.7470
USD/CHF
0.9235
USD/CAD
1.2661
EUR/JPY
129.7966

Asian Stocks Mixed As Beijing Strives to Control Xinfadai Outbreak


17 June 2020

Asian stocks were mixed on Wednesday, with investors weighing the equity market’s recent global rally against evidence that the fight against COVID-19 will be a long and tough one.

China’s Shanghai Composite fell 0.35% while the SZSE Component gained 0.03% by 10:52 PM ET (3:52 AM GMT), with capital city Beijing shutting schools and lifting its emergency level to level two to curb a weekend outbreak from Xinfadi market.

Some U.S. states such as Florida and Texas are seeing an uptick in cases and hospitalizations, sparking fears of a second wave of cases globally.

Meanwhile, India claimed 20 soldiers had been killed and China also reported casualties after clashes between the two countries earlier this week, the culmination of hundreds of soldiers facing off in three locations since early May.

Investor sentiment further soured after International Monetary Fund (IMF) chief economist Gita Gopinath warned in his blog post on Tuesday that “the forthcoming June World Economic Outlook Update is expected to show negative growth rates even worse than previously estimated.” The IMF added that the current crisis, which it christened the Great Lockdown, is “unlike anything the world has seen before.”

Meanwhile, the U.K. said that trial results announced on Tuesday showed that dexamethasone, which is widely available, could help critically ill COVID-19 patients by reportedly reducing deaths in hospitalized patients by up to one third. China’s National Biotech Group also said on Wednesday that phase II human clinical trial results showed that its COVID-19 vaccine is generally safe and able to generate an immune response. National Biotech Group is now looking to conduct clinical trials outside China.

#source

Related

Space tourism takes off and opens colossal market
Space tourism takes off and opens colossal market

Space tourism is definitely on the rise. According to Bank of America Merrill Lynch, it could represent USD 2.700 billion by 2045, against 400 billion today...

24 Sep 2021

All Eyes On The BOE Meeting
All Eyes On The BOE Meeting

US and European futures are trading higher today, following the Fed’s announcement yesterday that the economy is exhibiting signs of strength and...

23 Sep 2021

Stocks steady on Evergrande debt assurance
Stocks steady on Evergrande debt assurance

Equities were mostly recovering on Wednesday as market nerves were somewhat calmed after China’s troubled property giant, Evergrande, told investors it will meet

23 Sep 2021

Stock Futures Trade Sharply Lower
Stock Futures Trade Sharply Lower

Futures in the United States and in Europe are trading sharply lower as investors worry about the domino effect of Evergrande’s massive plunge on the Chinese property market..

21 Sep 2021

Oil market: the unbalanced demand and supply
Oil market: the unbalanced demand and supply

Oil prices climbed to higher grounds in the most recent daily sessions adding further to its upward momentum formed so far in September. The Oil market is running...

21 Sep 2021

US Markets lost major support, Asian Indices are melting
US Markets lost major support, Asian Indices are melting

Global markets closed last week on the back foot, and no significant positive factors emerged in Asian trading, increasing the flight to safety. The Hang Seng lost...

20 Sep 2021


Editors' Picks

OctaFX information and reviews
OctaFX
86%
HotForex information and reviews
HotForex
85%
XM information and reviews
XM
80%
FXCM information and reviews
FXCM
79%
Vantage FX information and reviews
Vantage FX
78%
Moneta Markets information and reviews
Moneta Markets
77%

© 2006-2021 Forex-Ratings.com

The usage of this website constitutes acceptance of the following legal information.
Any contracts of financial instruments offered to conclude bear high risks and may result in the full loss of the deposited funds. Prior to making transactions one should get acquainted with the risks to which they relate. All the information featured on the website (reviews, brokers' news, comments, analysis, quotes, forecasts or other information materials provided by Forex Ratings, as well as information provided by the partners), including graphical information about the forex companies, brokers and dealing desks, is intended solely for informational purposes, is not a means of advertising them, and doesn't imply direct instructions for investing. Forex Ratings shall not be liable for any loss, including unlimited loss of funds, which may arise directly or indirectly from the usage of this information. The editorial staff of the website does not bear any responsibility whatsoever for the content of the comments or reviews made by the site users about the forex companies. The entire responsibility for the contents rests with the commentators. Reprint of the materials is available only with the permission of the editorial staff.
We use cookies to improve your experience and to make your stay with us more comfortable. By using Forex-Ratings.com website you agree to the cookies policy.